Incyte Corporation vs Kinder Morgan Inc — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Kinder Morgan Inc trades at $32.47 (market cap $72.48B). The key difference: Kinder Morgan Inc is far larger — about 3.1× Incyte Corporation's market cap, and Kinder Morgan Inc pays a 3.61% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | KMI | |
|---|---|---|
Market Cap | $23.11B | $72.48B |
Sector | Health | Energy |
52-Week High | $118.52 | $34.31 |
52-Week Low | $67.38 | $25.84 |
Enterprise Value | $19.13B | $104.36B |
Dividend Yield | — | 3.61% |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →